talapro-1: phase ii study of talazoparib in patients with dna damage repair alterations and mcrpc
Published 3 years ago • 125 plays • Length 5:52Download video MP4
Download video MP3
Similar videos
-
5:01
talazoparib plus enzalutamide shows improvement in pfs over soc in first-line hrr mcrpc
-
1:44
talapro-2: exposure-safety of talazoparib enzalutamide in mcrpc
-
0:39
talapro-2: rpfs and os of talazoparib and enzalutamide in mcrpc
-
18:58
talapro-2 study of talazoparib/enzalutamide in prostate cancer: stephen freedland and neeraj agarwal
-
27:02
mcrpc: latest developments in diagnostics and combination therapies
-
16:07
profound trial shows increased rpfs in mcrpc patients with brca1, brca2, and atm mutations
-
12:20
parp inhibitors in prostate cancer: choices of tests and how to test?
-
21:21
role of immunotherapy and parp inhibitors
-
17:44
asco 2021: latest on parpi and other treatments for mcrpc
-
1:27
dr. petrylak on pivotal parp inhibitor trials in mcrpc with dna repair mutations
-
11:19
drs. fizazi, wallis on updated data from talapro-2
-
1:50
dr. hussain on the rationale to target the dna repair pathway in mcrpc
-
1:37
dr. agarwal on the talapro-2 trial in mcrpc
-
1:31
prevalence of ddr alterations in patients with mhspc enrolled in arches: next steps
-
31:57
episode 1 - talking prostate cancer: homologous recombination repair gene mutation testing in met...
-
3:06
titan trial
-
0:14
parp inhibitors simplified
-
4:37
triton2: evaluation of rucaparib in patients with metastatic castration-resistant prostate cancer